<p>/PRNewswire/ -- Pomerantz LLP 宣布对 Regencell Bioscience Holdings Limited（&#34;Regencell&#34; 或 &#34;公司&#34;）（NASDAQ: RGC）及某些高管提起了集体诉讼。该集体诉讼在美国马里兰州地方法院提起，案号为 26-cv-01602，代表所有在 2024 年 10 月 28 日至 2025 年 10 月 31 日（包括这两个日期）期间购买或以其他方式获得 Regencell 证券的个人和实体（&#34;集体成员&#34;），寻求因被告违反联邦证券法而造成的损害赔偿，并根据 1934 年证券交易法第 10(b) 和 20(a) 条款及其下颁布的第 10b-5 规则对公司及其某些高管追求救济。</p>
<p>如果您是于集体诉讼期间购买或以其他方式获得 Regencell 证券的投资者，您有直到 2026 年 6 月 23 日的时间请求法院任命您为集体的首席原告。投诉的副本可以在 www.pomerantzlaw.com 获取。如需讨论此诉讼，请联系 Danielle Peyton，电子邮件地址为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免付费，分机 7980。通过电子邮件询问的人士被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
<p><strong>[点击此处获取有关加入集体诉讼的信息]</strong></p>
<p>Regencell 是一家声称处于早期阶段的生物科学公司，专注于传统中医（&#34;TCM&#34;）的研究、开发和商业化，以治疗注意力缺陷/多动障碍（&#34;ADHD&#34;）和自闭症谱系障碍（&#34;ASD&#34;）——这两种疾病在当前医学共识下通常被认为是无法治愈的。公司声称，虽然 &#34;[c] urrently available drugs and treatments in the markets for ADHD and ASD aim to suppress or alleviate symptoms,&#34; 其 &#34;TCM 配方旨在治疗 <strong><em>神经认知障碍的根本原因</em></strong>。&#34;（强调已添加。）</p>
<p>Regencell 是纳斯达克资本市场规则下的 &#34;受控公司&#34;。根据 Regencell 最近提交的 20-F 表格年报，截至 2025 年 6 月 30 日，88.8% 的股份由其董事和高管持有，其中 88.6% 的股份由被告 Yat-Gai Au（&#34;Au&#34;）拥有——公司的创始人、董事长和首席执行官。如今，88.56% 的 Regencell 股份由内部人士持有，其中绝大多数股份仍然可能在被告 Au 手中。</p>
<p>在集体诉讼期间开始至大约 2025 年 3 月中旬，Regencell 的普通股通常交易价格低于每股 30 美分。然而，从 2025 年 5 月初开始，这些股票的价格突然飙升，在 2025 年 6 月 17 日以每股 <strong><em>$78.00</em></strong> 的集体诉讼期间最高价收盘——比集体诉讼开始时上涨了 <strong><em>48,650%</em></strong>，比仅一周前上涨了大约 <strong><em>382%</em></strong>。到下周，公司股价暴跌，收盘价仅略高于每股 20.00 美元。在投诉提交时，Regencell 的普通股交易价格在每股 27.00 到 29.00 美元之间，三个月的平均交易量约为 167,380 股。</p>
<p>Regencell 普通股价格的迅猛上涨与其基本业务基本面没有明显的关联。Regencell 只有十二名员工，没有获得批准或可销售的产品，没有收入，自成立以来一直在亏损。此外，尽管其声称的目标是治愈被广泛认为无法治愈的医疗疾病，但公司的研究与开发（&#34;R&amp;D&#34;）成本在截至 2025 年和 2024 年的年度分别仅为 0.95 百万美元和 1.07 百万美元。这与 Regencell 自己的表述形成鲜明对比，后者称 &#34;[a] verage [R&amp;D] to marketplace cost for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion.&#34; 公司自己承认 &#34;我们的股价经历了极端的价格和交易量波动，这些波动往往与我们公司的经营表现无关或不成比例。&#34;</p>
<p>尽管如此，Regencell 的市值约为 <strong><em>$140 亿</em></strong>。正如《华尔街日报》在 2026 年 1 月所观察到的，&#34;[f] or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell.&#34;</p>
<p>在所有相关时间内，被告淡化了 Regencell 普通股市场波动的可能性和严重性，或淡化了市场操纵在产生该波动中的潜在作用。事实上，被告将任何波动主要归因于卖空活动和未确定的第三方新闻及社交媒体活动。</p>
<p>投诉指控，在集体诉讼期间，被告对公司的业务、运营和合规政策做出了实质性虚假和误导性的陈述。具体而言，被告做出了虚假和/或误导性的陈述，和/或未能披露以下内容：(i) Regencell 易受市场操纵的影响；(ii) 由此导致的公司普通股市场波动使 Regencell 的投资者面临重大财务风险；(iii) 所有上述情况使 Regencell 面临更高的监管和/或政府审查及执法行动的风险，以及重大法律、经济和声誉损害；(iv) 因此，被告的公开声明在所有相关时间内都是实质性虚假和误导的。</p>
<p>真相开始在 2025 年 10 月 31 日浮出水面，当时 Regencell 在向美国证券交易委员会提交的文件中披露，&#34;在我们普通股市场近期波动之后，公司收到了来自美国司法部（'DOJ'）的信件和传票，表明 DOJ 正在对我们普通股的交易进行调查。&#34; Regencell 表示，&#34;DOJ 已请求提供与这些及其他公司运营、财务和会计事务相关的文件和通讯&#34;，并且公司&#34;预计在回应调查时将继续产生重大法律费用和其他支出&#34;，并且&#34;可能需要支付超过我们保险覆盖范围的罚款、赔偿金或和解费用（如果有的话），与调查相关。&#34;</p>
<p>在这一消息发布后，Regencell 的普通股股价在 2025 年 11 月 3 日下跌了 3.09 美元，或 18.56%，收于每股 13.56 美元。</p>
<p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为企业、证券和反垄断集体诉讼领域的顶尖律所之一。该公司由已故的亚伯拉罕·L·波梅兰茨创立，他被称为集体诉讼领域的开创者，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、违反信托责任和公司不当行为的受害者争取权利。该公司已为集体成员追回了数十亿美元的赔偿金。请访问 www.pomlaw.com。</p>
<p>律师广告。以往的结果并不保证类似的结果。</p>
<p>联系方式：</p>
<p>Danielle Peyton</p>
<p>Pomerantz LLP</p>
<p>[email protected]</p>
<p>646-581-9980 ext. 7980</p>
<p>来源 Pomerantz LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQ1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMTUzUFJfTkVXU19VU1BSX19fX19EQzYwNDUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQ1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMTUzUFJfTkVXU19VU1BSX19fX19EQzYwNDUw"/></p>

脑再生科技

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

<p>Pomerantz LLP 已对 Regencell Bioscience Holdings Limited 及其部分高管提起集体诉讼，指控其违反联邦证券法。该诉讼涵盖了在 2024 年 10 月 28 日至 2025 年 10 月 31 日期间购买 Regencell 证券的投资者。投诉中强调了 Regencell 股票价格的显著波动，尽管公司没有任何获批产品或收入，但其股价却大幅上涨。投资者有直到 2026 年 6 月 23 日的时间申请成为主诉人</p>

<p>, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (&#34;Regencell&#34; or the &#34;Company&#34;) (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the &#34;Class Period&#34;), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Pomerantz LLP 宣布对 Regencell Bioscience Holdings Limited（&#34;Regencell&#34; 或 &#34;公司&#34;）（NASDAQ: RGC）及某些高管提起了集体诉讼。该集体诉讼在美国马里兰州地方法院提起，案号为 26-cv-01602，代表所有在 2024 年 10 月 28 日至 2025 年 10 月 31 日（包括这两个日期）期间购买或以其他方式获得 Regencell 证券的个人和实体（&#34;集体成员&#34;），寻求因被告违反联邦证券法而造成的损害赔偿，并根据 1934 年证券交易法第 10(b) 和 20(a) 条款及其下颁布的第 10b-5 规则对公司及其某些高管追求救济。</p>
</div><p>If you are an investor who purchased or otherwise acquired Regencell securities during the Class Period, you have until June 23, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.</p>
<div class="lb-trans"><p>如果您是于集体诉讼期间购买或以其他方式获得 Regencell 证券的投资者，您有直到 2026 年 6 月 23 日的时间请求法院任命您为集体的首席原告。投诉的副本可以在 www.pomerantzlaw.com 获取。如需讨论此诉讼，请联系 Danielle Peyton，电子邮件地址为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免付费，分机 7980。通过电子邮件询问的人士被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
</div><p><strong>[Click here for information about joining the class action]</strong></p>
<div class="lb-trans"><p><strong>[点击此处获取有关加入集体诉讼的信息]</strong></p>
</div><p>Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (&#34;TCM&#34;) for the treatment of attention-deficit/hyperactivity disorder (&#34;ADHD&#34;) and autism spectrum disorder (&#34;ASD&#34;)—two disorders generally considered incurable under current medical consensus. The Company asserts that while &#34;[c] urrently available drugs and treatments in the markets for ADHD and ASD aim to suppress or alleviate symptoms,&#34; its &#34;TCM formula aim[s] to treat <strong><em>the fundamental cause</em></strong> of neurocognitive disorders.&#34; (Emphasis added.)</p>
<div class="lb-trans"><p>Regencell 是一家声称处于早期阶段的生物科学公司，专注于传统中医（&#34;TCM&#34;）的研究、开发和商业化，以治疗注意力缺陷/多动障碍（&#34;ADHD&#34;）和自闭症谱系障碍（&#34;ASD&#34;）——这两种疾病在当前医学共识下通常被认为是无法治愈的。公司声称，虽然 &#34;[c] urrently available drugs and treatments in the markets for ADHD and ASD aim to suppress or alleviate symptoms,&#34; 其 &#34;TCM 配方旨在治疗 <strong><em>神经认知障碍的根本原因</em></strong>。&#34;（强调已添加。）</p>
</div><p>Regencell is a &#34;controlled company&#34; under the Nasdaq Capital Market's rules. Per Regencell's most recent annual report on Form 20-F, as of June 30, 2025, 88.8% of its shares were held by its directors and executive officers, with 88.6% of those shares owned by Defendant Yat-Gai Au (&#34;Au&#34;)—the Company's founder, Chairman, and Chief Executive Officer. Today, 88.56% of Regencell's shares are held by insiders, with the vast majority of those shares still presumably in the hands of Defendant Au.</p>
<div class="lb-trans"><p>Regencell 是纳斯达克资本市场规则下的 &#34;受控公司&#34;。根据 Regencell 最近提交的 20-F 表格年报，截至 2025 年 6 月 30 日，88.8% 的股份由其董事和高管持有，其中 88.6% 的股份由被告 Yat-Gai Au（&#34;Au&#34;）拥有——公司的创始人、董事长和首席执行官。如今，88.56% 的 Regencell 股份由内部人士持有，其中绝大多数股份仍然可能在被告 Au 手中。</p>
</div><p>From the start of the Class Period through approximately mid-March 2025, Regencell's ordinary shares generally traded at less than 30 cents per share. However, beginning in early May 2025, the price for these shares suddenly skyrocketed, closing at a Class Period high of <strong><em>$78.00</em></strong> per share on June 17, 2025—a <strong><em>48,650%</em></strong> increase from the start of the Class Period and an approximately <strong><em>382%</em></strong> increase from just a week prior. By the following week, the Company's share price had plummeted, closing in a range only slightly higher than $20.00 per share. As of the time of the filing of the complaint, Regencell's ordinary shares traded around $27.00 to $29.00 per share, with a three-month average trading volume of approximately 167,380 shares.</p>
<div class="lb-trans"><p>在集体诉讼期间开始至大约 2025 年 3 月中旬，Regencell 的普通股通常交易价格低于每股 30 美分。然而，从 2025 年 5 月初开始，这些股票的价格突然飙升，在 2025 年 6 月 17 日以每股 <strong><em>$78.00</em></strong> 的集体诉讼期间最高价收盘——比集体诉讼开始时上涨了 <strong><em>48,650%</em></strong>，比仅一周前上涨了大约 <strong><em>382%</em></strong>。到下周，公司股价暴跌，收盘价仅略高于每股 20.00 美元。在投诉提交时，Regencell 的普通股交易价格在每股 27.00 到 29.00 美元之间，三个月的平均交易量约为 167,380 股。</p>
</div><p>The meteoric rise in Regencell's ordinary share price has no evident connection to any public disclosures regarding its underlying business fundamentals. Regencell has twelve employees, no approved or salable products, no revenue, and has incurred operating losses since its formation. Further, notwithstanding its stated goal of curing medical disorders that are widely considered incurable, the Company's research and development (&#34;R&amp;D&#34;) costs were only $0.95 million and $1.07 million for the years ended June 30, 2025 and 2024, respectively. This stands in stark contrast with Regencell's own representations that &#34;[a] verage [R&amp;D] to marketplace cost for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion.&#34; The Company itself has admitted that &#34;our stock price has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our company.&#34;</p>
<div class="lb-trans"><p>Regencell 普通股价格的迅猛上涨与其基本业务基本面没有明显的关联。Regencell 只有十二名员工，没有获得批准或可销售的产品，没有收入，自成立以来一直在亏损。此外，尽管其声称的目标是治愈被广泛认为无法治愈的医疗疾病，但公司的研究与开发（&#34;R&amp;D&#34;）成本在截至 2025 年和 2024 年的年度分别仅为 0.95 百万美元和 1.07 百万美元。这与 Regencell 自己的表述形成鲜明对比，后者称 &#34;[a] verage [R&amp;D] to marketplace cost for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion.&#34; 公司自己承认 &#34;我们的股价经历了极端的价格和交易量波动，这些波动往往与我们公司的经营表现无关或不成比例。&#34;</p>
</div><p>Notwithstanding the foregoing, Regencell has a market value of approximately <strong><em>$14 billion</em></strong>. As <em>The Wall Street Journal</em> observed in January 2026, &#34;[f] or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell.&#34;</p>
<div class="lb-trans"><p>尽管如此，Regencell 的市值约为 <strong><em>$140 亿</em></strong>。正如《华尔街日报》在 2026 年 1 月所观察到的，&#34;[f] or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell.&#34;</p>
</div><p>At all relevant times, Defendants downplayed the likelihood and severity of, and/or risks related to, volatility in the market for Regencell's ordinary shares, or else downplayed the potential role of market manipulation in generating said volatility. Indeed, Defendants attributed any volatility largely to short-selling activity and unidentified third-party news and social media activity.</p>
<div class="lb-trans"><p>在所有相关时间内，被告淡化了 Regencell 普通股市场波动的可能性和严重性，或淡化了市场操纵在产生该波动中的潜在作用。事实上，被告将任何波动主要归因于卖空活动和未确定的第三方新闻及社交媒体活动。</p>
</div><p>The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.</p>
<div class="lb-trans"><p>投诉指控，在集体诉讼期间，被告对公司的业务、运营和合规政策做出了实质性虚假和误导性的陈述。具体而言，被告做出了虚假和/或误导性的陈述，和/或未能披露以下内容：(i) Regencell 易受市场操纵的影响；(ii) 由此导致的公司普通股市场波动使 Regencell 的投资者面临重大财务风险；(iii) 所有上述情况使 Regencell 面临更高的监管和/或政府审查及执法行动的风险，以及重大法律、经济和声誉损害；(iv) 因此，被告的公开声明在所有相关时间内都是实质性虚假和误导的。</p>
</div><p>The truth began to emerge on October 31, 2025, when Regencell disclosed in a filing with the U.S. Securities and Exchange Commission that &#34;following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the United States Department of Justice ('DOJ'), indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares.&#34; Regencell said that &#34;[t] he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters&#34; and that the Company &#34;expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation&#34; and &#34;may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation.&#34;</p>
<div class="lb-trans"><p>真相开始在 2025 年 10 月 31 日浮出水面，当时 Regencell 在向美国证券交易委员会提交的文件中披露，&#34;在我们普通股市场近期波动之后，公司收到了来自美国司法部（'DOJ'）的信件和传票，表明 DOJ 正在对我们普通股的交易进行调查。&#34; Regencell 表示，&#34;DOJ 已请求提供与这些及其他公司运营、财务和会计事务相关的文件和通讯&#34;，并且公司&#34;预计在回应调查时将继续产生重大法律费用和其他支出&#34;，并且&#34;可能需要支付超过我们保险覆盖范围的罚款、赔偿金或和解费用（如果有的话），与调查相关。&#34;</p>
</div><p>On this news, Regencell's ordinary share price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025.</p>
<div class="lb-trans"><p>在这一消息发布后，Regencell 的普通股股价在 2025 年 11 月 3 日下跌了 3.09 美元，或 18.56%，收于每股 13.56 美元。</p>
</div><p>Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.</p>
<div class="lb-trans"><p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为企业、证券和反垄断集体诉讼领域的顶尖律所之一。该公司由已故的亚伯拉罕·L·波梅兰茨创立，他被称为集体诉讼领域的开创者，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、违反信托责任和公司不当行为的受害者争取权利。该公司已为集体成员追回了数十亿美元的赔偿金。请访问 www.pomlaw.com。</p>
</div><p>Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p>律师广告。以往的结果并不保证类似的结果。</p>
</div><p>CONTACT:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Danielle Peyton</p>
<div class="lb-trans"><p>Danielle Peyton</p>
</div><p>Pomerantz LLP</p>
<div class="lb-trans"><p>Pomerantz LLP</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>646-581-9980 ext. 7980</p>
<div class="lb-trans"><p>646-581-9980 ext. 7980</p>
</div><p>SOURCE Pomerantz LLP</p>
<div class="lb-trans"><p>来源 Pomerantz LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDQ1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMTUzUFJfTkVXU19VU1BSX19fX19EQzYwNDUw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC60450&amp;Transmission_Id=202605142153PR_NEWS_USPR_____DC60450&amp;DateId=20260514"/></p>

21:53 ETPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited   and Certain Officers - RGC

prnewswire

Pomerantz 律师事务所宣布对脑再生科技控股有限公司及某些高管提起集体诉讼 - RGC